Exploring IN8bio, Inc. (INAB) Investor Profile: Who’s Buying and Why?

Are you keeping tabs on IN8bio, Inc. (INAB) and wondering who's investing and why? As of April 16, 2025, the share price stands at $0.16, a significant 84.24% decline from its price of $1.00 on April 17, 2024. Currently, 37 institutional owners and shareholders have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC), holding a total of 30,384,388 shares. Want to delve deeper into the key players and their recent moves? Keep reading to uncover the dynamics shaping IN8bio's investor landscape.

IN8bio, Inc. (INAB) Who Invests in IN8bio, Inc. (INAB) and Why?

Understanding the investor profile of IN8bio, Inc. (INAB) involves examining the various types of investors, their motivations, and the strategies they employ. This provides valuable insights into the market's perception of the company and its future prospects. To delve deeper into the company's background, mission, and operational aspects, you can explore: IN8bio, Inc. (INAB): History, Ownership, Mission, How It Works & Makes Money

Key investor types in IN8bio, Inc. (INAB) typically include:

• Retail Investors: Individual investors who buy and sell shares for their own accounts.
• Institutional Investors: Entities such as mutual funds, pension funds, insurance companies, and hedge funds that invest on behalf of others.
• Hedge Funds: Investment partnerships that use pooled funds and employ various strategies to earn active return for their investors.

These different investor groups often have varying investment horizons and risk tolerances, influencing their trading behavior and impact on IN8bio, Inc. (INAB)'s stock price.

Several factors attract investors to IN8bio, Inc. (INAB):

• Growth Prospects: Investors are drawn to IN8bio, Inc. (INAB)'s potential for significant growth in the biotechnology sector, particularly in the field of cancer therapies.
• Market Position: The company's competitive positioning and innovative approaches in its specific market niche can be a strong motivator.

Investment strategies among IN8bio, Inc. (INAB) investors can vary widely:

• Long-Term Holding: Some investors adopt a long-term perspective, holding shares for an extended period to benefit from the anticipated growth and success of IN8bio, Inc. (INAB).
• Short-Term Trading: Other investors engage in short-term trading, seeking to profit from the stock's price fluctuations.
• Value Investing: Value investors may see IN8bio, Inc. (INAB) as undervalued by the market and invest with the expectation that its true value will eventually be recognized.

To illustrate the ownership structure, consider the following hypothetical data. Please note that the following table is for illustrative purposes and does not reflect real-time ownership data.

Understanding the composition and strategies of IN8bio, Inc. (INAB)'s investor base is crucial for assessing market sentiment and potential stock performance.

IN8bio, Inc. (INAB) Institutional Ownership and Major Shareholders

Understanding the institutional ownership of IN8bio, Inc. (INAB) provides valuable insights into the company's investor base and market sentiment. Institutional investors, which include mutual funds, hedge funds, pension funds, and other large investment firms, often have a significant impact on a company's stock price and overall strategy. Their investment decisions can signal confidence in the company's future prospects or concerns about potential risks.

As of the latest available data, several institutional investors hold substantial positions in IN8bio, Inc. (INAB). While specific holdings can change frequently, some of the top institutional investors typically include well-known firms specializing in healthcare or biotechnology investments. These firms conduct extensive research and analysis before investing, and their decisions can influence the perceptions of other investors.

Examining changes in institutional ownership can reveal important trends. An increase in institutional holdings may indicate growing confidence in IN8bio, Inc. (INAB)'s pipeline, clinical trial results, or market potential. Conversely, a decrease in holdings could suggest concerns about regulatory hurdles, competition, or financial performance. Monitoring these changes over time provides a dynamic view of investor sentiment.

The role of these large investors extends beyond simply holding shares. They often engage with the company's management, providing feedback on strategy, governance, and operations. Their influence can help shape key decisions and ensure that the company remains focused on creating long-term value for shareholders. The presence of reputable institutional investors can also enhance the company's credibility and attract additional investment.

Here’s a general overview of what to consider when evaluating institutional ownership:

• Identify Top Holders: Determine which institutions hold the largest positions in IN8bio, Inc. (INAB).
• Track Changes: Monitor whether these institutions are increasing or decreasing their positions.
• Assess Impact: Analyze how these changes might affect the stock price and company strategy.
• Consider Engagement: Understand the level of engagement these investors have with company management.

Institutional investors play a crucial role in IN8bio, Inc. (INAB)'s market dynamics. Their actions reflect deep research and substantial investment theses, making their activity a key indicator for other investors. Keeping an eye on these trends can offer valuable perspectives on the company's health and future direction.

For more insights into IN8bio, Inc. (INAB)'s financial standing, consider reading: Breaking Down IN8bio, Inc. (INAB) Financial Health: Key Insights for Investors

IN8bio, Inc. (INAB) Key Investors and Their Impact on IN8bio, Inc. (INAB)

Understanding the investor profile of IN8bio, Inc. (INAB) provides valuable insights into the company's stability, growth potential, and market perception. Key investors can significantly influence company decisions and stock movements through their holdings and strategic actions.

As of April 2025, 37 institutional owners and shareholders have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC), holding a total of 30,384,388 shares. Institutional investors hold approximately 29.05% of the company's stock.

Here are some of the largest shareholders:

• BIOS Capital Management, LP
• AIGH Capital Management LLC
• Franklin Resources Inc
• Alyeska Investment Group, L.P.
• Vanguard Group Inc
• Sigma Planning Corp
• VTSMX - Vanguard Total Stock Market Index Fund Investor Shares
• 683 Capital Management, LLC
• Geode Capital Management, Llc
• VEXMX - Vanguard Extended Market Index Fund Investor Shares

Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. A Schedule 13D filing indicates that the investor holds (or held) more than 5% of the company and intends (or intended) to actively pursue a change in business strategy. A Schedule 13G indicates a passive investment of over 5%.

Recent moves by some of these investors include:

• Franklin Resources Inc added 5,696,202 shares (∞%) to their portfolio in Q4 2024, with an estimated value of $1,465,063.
• ALYESKA INVESTMENT GROUP, L.P. added 4,628,482 shares (+1064.5%) to their portfolio in Q4 2024, for an estimated $1,190,445.
• AIGH CAPITAL MANAGEMENT LLC added 4,517,227 shares (+269.7%) to their portfolio in Q4 2024, for an estimated $1,161,830.
• ENSIGN PEAK ADVISORS, INC removed 829,176 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $213,264.
• 683 CAPITAL MANAGEMENT, LLC removed 600,304 shares (-44.5%) from their portfolio in Q4 2024, for an estimated $154,398.
• SIGMA PLANNING CORP added 190,100 shares (+22.3%) to their portfolio in Q4 2024, for an estimated $48,893.
• GEODE CAPITAL MANAGEMENT, LLC added 185,919 shares (+56.5%) to their portfolio in Q4 2024, for an estimated $47,818.

Activist investors can also play a role. For example, William Tai-Wei Ho reported owning 4,098,800 shares as of February 14, 2025.

It's worth noting that IN8bio's stock has experienced significant volatility. As of April 16, 2025, the share price was $0.16, a decrease of 84.24% from $1.00 on April 17, 2024. In March 2025, the stock touched a 52-week low of $0.16 and $0.21 amid this sharp annual decline. Despite these challenges, analyst price targets range from $1.20 to $7.50, suggesting potential recovery opportunities.

Recent positive Phase 1 trial results for IN8bio's INB-100 therapy have led to some analysts upgrading the stock rating, though H.C. Wainwright lowered the price target from $8.00 to $6.00, citing the dilutive effect of a recent capital raise. The company maintains a current ratio of 4.08 and holds more cash than debt, despite its small market capitalization of $13.57 million to $18 million.

Institutional ownership can significantly impact a company's stock. A high percentage of institutional ownership can provide stability, as these investors typically have a longer-term investment horizon. However, it can also lead to increased volatility if these institutions decide to sell their shares.

Understanding these investor dynamics is crucial for anyone looking to invest in IN8bio, Inc. (INAB). For more insights into the company's financial health, consider reading Breaking Down IN8bio, Inc. (INAB) Financial Health: Key Insights for Investors.

IN8bio, Inc. (INAB) Market Impact and Investor Sentiment

Understanding investor sentiment and market reactions is crucial for evaluating the potential of IN8bio, Inc. (INAB). Examining the moves of major shareholders, recent market behaviors, and analyst perspectives provides a comprehensive view of the company's current standing and future prospects.

Investor Sentiment: The prevailing sentiment among major shareholders significantly influences IN8bio, Inc. (INAB)'s stock performance. Positive sentiment typically leads to increased investment and stock appreciation, while negative sentiment can result in sell-offs and decreased valuation. While specific, real-time sentiment data for major shareholders requires continuous monitoring of filings and market analysis, keeping abreast of these indicators is vital. As of now, without direct access to up-to-the-minute proprietary data, a general assessment would rely on the observation of trading patterns and reported positions.

Recent Market Reactions: Stock market reactions to changes in ownership or large investor moves can offer insights into market confidence in IN8bio, Inc. (INAB). Significant investments by institutional investors often lead to a positive market response, signaling trust in the company’s direction and potential. Conversely, large-scale divestments can trigger concerns and downward pressure on the stock price. Monitoring these reactions helps to gauge the market's short-term and medium-term outlook on the company. For instance, any announcements of clinical trial results would heavily influence market sentiment. Actual market reactions should be derived from real-time stock performance data following major announcements.

Analyst Perspectives: Financial analysts' insights play a crucial role in shaping investor perception of IN8bio, Inc. (INAB). Analysts' ratings, price targets, and detailed reports provide a professional assessment of the company’s financial health, growth potential, and competitive positioning. These perspectives often influence both retail and institutional investors. Recent analyst reports can offer a balanced view, incorporating both the strengths and weaknesses of IN8bio, Inc. (INAB), and projecting future performance based on various factors such as clinical trial outcomes and market conditions. Always refer to the latest available analyst reports for the most current evaluations. As an example, analysts might focus on the potential of IN8bio's cell therapy technologies or their progress in clinical trials. Here is a sample of what analysts typically consider:

• Clinical Trial Progress
• Financial Stability
• Market Opportunities
• Competitive Landscape

Keeping a close watch on these elements allows stakeholders to make well-informed decisions about IN8bio, Inc. (INAB). For more insights into the company's foundational aspects, you might find this resource useful: Mission Statement, Vision, & Core Values of IN8bio, Inc. (INAB).